Dare Bioscience (DARE) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.Sale William H. Rastetter, Director sold 859 shares at $0.45 ($382).
- Trade date
- Nov 19, 2026
- Disclosed to the SEC
- Nov 20, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All DARE insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
DARE insider transactions (Form 4)
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 20 NewSEC | William H. RastetterDirector | Sell | 859 | $0.45 | $382 | — | — |
Similar past setups: not applicable. DARE has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with DARE in the Research Lab
DARE has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Price history unavailable.
Dare Bioscience insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 1 sold $382 of DARE stock on the open market.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings · How we calculate this
DARE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $382 | 1 |
Valuation, profit and volume
Valuation figures for DARE are refreshed each weekday; some aren't published for every company. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Dare Bioscience, Inc. insiders reported open-market purchases totaling $0, while 1 insider reported sales totaling $382. 0 of 1 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insiders at Dare Bioscience, Inc.
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| William H. RastetterDirector | — | $382 | Nov 20, 2026 | — | — |
Board links: companies that share insiders with DARE
Directors and executives who filed Form 4s for DARE and another company in the last 12 months.
- NBIXNeurocrine Biosciences William H. Rastetter Director here · Director at NBIX · latest filing Nov 20, 2026
DARE stock: common questions
Are Dare Bioscience, Inc. insiders buying DARE stock?
No. No Dare Bioscience, Inc. insider reported an open-market purchase of DARE in the past 12 months.
Are Dare Bioscience, Inc. insiders selling DARE stock?
1 insider reported sales worth $382 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.